A 38-year-old woman presents to the psychiatry clinic with a 3-month history of persistent low mood, loss of interest in her job and hobbies, early morning awakening at 4 AM, and significant weight loss of 8 kg. She reports feeling worthless and has had passive suicidal ideation without a plan. Her sleep is fragmented, and she describes her mood as worse in the mornings. She denies any recent psychosocial stressors. Physical examination is unremarkable. Thyroid function tests and CBC are normal. What is the most appropriate first-line pharmacological intervention?

Explanation

## Diagnosis and Treatment Rationale This patient meets DSM-5 criteria for Major Depressive Disorder with melancholic features (early morning awakening, diurnal mood variation, anhedonia, weight loss, psychomotor changes, and feelings of worthlessness). ### Key Clinical Features **Key Point:** The presence of melancholic features (anhedonia, early morning awakening, worse mood in morning, significant weight loss, guilt/worthlessness) indicates more severe depression and better response to biological interventions. ### First-Line Pharmacotherapy **High-Yield:** SSRIs (selective serotonin reuptake inhibitors) are the first-line agents for MDD across all subtypes, including melancholic depression. Fluoxetine is a commonly used SSRI with good efficacy and tolerability. | Feature | SSRI (Fluoxetine) | Lithium | Antipsychotic | Benzodiazepine | | --- | --- | --- | --- | --- | | First-line for MDD | Yes | No (augmentation) | Only with psychosis | No | | Efficacy in melancholia | Good | Augmentation only | If psychotic features | Ineffective monotherapy | | Safety profile | Favorable | Narrow therapeutic index | Extrapyramidal risk | Dependence risk | | Onset of action | 2–4 weeks | N/A | 2–4 weeks | Immediate (not therapeutic) | ### Why Fluoxetine 20 mg Daily? 1. **SSRI efficacy:** SSRIs are the gold standard first-line agents for MDD, with response rates of 50–60% and remission rates of 30–40% [cite:DSM-5 Diagnostic Criteria]. 2. **Melancholic depression:** Melancholic features respond well to SSRIs and tricyclic antidepressants; biological interventions are preferred over psychotherapy alone. 3. **Safety:** SSRIs have a favorable side-effect profile and no need for blood monitoring, unlike lithium. 4. **Suicidal ideation:** SSRIs are safe in the presence of passive suicidal ideation (without plan); close monitoring is still required. **Clinical Pearl:** In melancholic depression, SSRIs are preferred over psychotherapy alone because the neurobiological substrate (serotonergic, noradrenergic dysregulation) responds to pharmacotherapy. ### Treatment Timeline - **Weeks 1–2:** Initiate fluoxetine 20 mg daily; monitor for activation or initial anxiety. - **Weeks 2–4:** Assess for early response (mood lift, sleep improvement). - **Weeks 4–6:** Full therapeutic effect expected; if partial response, consider dose escalation to 40 mg. - **Weeks 8–12:** Evaluate for remission; if inadequate response, consider augmentation (lithium, T3) or switch to another agent. **Mnemonic:** **SSRI-FIRST** — SSRIs are the first-line agents for MDD (regardless of subtype), with good efficacy and safety.